Literature DB >> 18352769

Treatment of recurrent ventriculoperitoneal shunt failure associated with persistent cerebrospinal fluid eosinophilia and latex allergy by use of an "extracted" shunt.

Michael J Ellis1, Colin J Kazina, Marc R Del Bigio, Patrick J McDonald.   

Abstract

Shunt failure is commonly associated with infection or mechanical obstruction of the shunt system. The presence of eosinophilia in the cerebrospinal fluid (CSF) has been associated with CSF shunt failure and may be related to both latex and shunt allergies. The authors describe the case of a child with a latex allergy who presented with 10 episodes of shunt failure over a period of 93 months. Cerebrospinal fluid sampling demonstrated persistent eosinophilia (3-36%) and negative cultures. Pathological examination of the ventricular catheter on 3 occasions demonstrated mechanical obstruction by inflammatory debris consisting largely of eosinophils and multinucleated giant cells. On the suspicion that the child might have some uncharacterized allergy to the shunt hardware, shunt replacement was performed using an "extracted" shunt system. The child has remained free of shunt malfunction for > 2 years since the last surgery. Immune responses to unpolymerized silicone are discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18352769     DOI: 10.3171/PED/2008/1/3/237

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  2 in total

Review 1.  Cerebrospinal Fluid Shunting Complications in Children.

Authors:  Brian W Hanak; Robert H Bonow; Carolyn A Harris; Samuel R Browd
Journal:  Pediatr Neurosurg       Date:  2017-03-02       Impact factor: 1.162

2.  Influence of congenital central nervous system malformations on postoperative complications following placement of cerebrospinal fluid shunts in pediatric and adolescent patients.

Authors:  Marina Raguz; Nikolina Brcina; Davor Marinac; Miroslav Gjurasin
Journal:  Wien Klin Wochenschr       Date:  2013-10-29       Impact factor: 1.704

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.